INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section
June 23, 2026
INESSS (the Institut national d’excellence en santé et en services sociaux) in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section!
Denosumab is currently available only through the exceptional patient measure administered by the Régie de l’assurance maladie du Québec (RAMQ), resulting in an administrative burden.
Clinicians have noted inequities in access to denosumab for the treatment of osteoporosis between men and women, a distinction that is not supported by any scientific justification. There is therefore a need to standardize practice across Quebec and address the observed inequalities in access to treatment.
These changes are expected to meaningfully support both patients and the health care system.
Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]
Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
July 7, 2026
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
